CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM.
Tien JC, et al. Among authors: zhou l.
Cell Rep Med. 2024 Sep 26:101758. doi: 10.1016/j.xcrm.2024.101758. Online ahead of print.
Cell Rep Med. 2024.
PMID: 39368479